UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

Clinical cancer research, 2015-12, Vol.21 (23), p.5205-5208

2015

Volltextzugriff (PDF)

FDA Approval Summary: Ramucirumab for Gastric Cancer

Clinical cancer research, 2015-08, Vol.21 (15), p.3372-3376

2015

Volltextzugriff (PDF)

FDA Approval Summary: TAS-102

Clinical cancer research, 2017-06, Vol.23 (12), p.2924-2927

2017

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Clinical cancer research, 2021-04, Vol.27 (7), p.1836-1841

2021

Volltextzugriff (PDF)

Tissue-Agnostic Drug Development: A New Path to Drug Approval

Cancer discovery, 2021-09, Vol.11 (9), p.2139-2144

2021

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Volltextzugriff (PDF)

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2024-01, Vol.30 (2), p.269

2024

Volltextzugriff (PDF)

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical cancer research, 2023-11, Vol.29 (21), p.4326

2023

Volltextzugriff (PDF)

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical cancer research, 2023-03, Vol.29 (5), p.838-842

2023

Volltextzugriff (PDF)

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical cancer research, 2023-10, Vol.29 (20), p.4027

2023

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical cancer research, 2022-12, Vol.28 (24), p.5244-5248

2022

Volltextzugriff (PDF)

FDA's Approach to Regulating Biosimilars

Clinical cancer research, 2017-04, Vol.23 (8), p.1882-1885

2017

Volltextzugriff (PDF)

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical cancer research, 2023-06, Vol.29 (11), p.2020-2024

2023

Volltextzugriff (PDF)

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical cancer research, 2021-11, Vol.27 (21), p.5753-5756

2021

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573

2023

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Clinical cancer research, 2010-09, Vol.16 (17), p.4331-4338

2010

Volltextzugriff (PDF)

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Cancer discovery, 2023-12, Vol.13 (12), p.2515

2023

Volltextzugriff (PDF)

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical cancer research, 2021-10, Vol.27 (19), p.5161-5167

2021

Volltextzugriff (PDF)

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop

Clinical cancer research, 2021-01, Vol.27 (2), p.394-401

2021

Volltextzugriff (PDF)

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

Clinical cancer research, 2012-03, Vol.18 (6), p.1496-1505

2012

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (1), p.97-104

2011

Volltextzugriff (PDF)

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

British journal of haematology, 2011-04, Vol.153 (1), p.66-75

2011

Volltextzugriff (PDF)

Biosimilars: Here and Now

American Society of Clinical Oncology educational book, 2016-05, Vol.35 (36), p.e151-e157

2016

Volltextzugriff (PDF)

When One Is a Hammer, Everything Looks Like a Nail

Journal of oncology practice, 2017-09, Vol.13 (9_suppl), p.10s

Lemery, Steven J

2017

Volltextzugriff (PDF)

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome

British journal of haematology, 2006-02, Vol.132 (3), p.286-292

2006

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(3)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(27)
NUS Single-Journal Subscriptions
(18)
Ovid SocietyJournals and Single Titles
(5)
Wiley-Blackwell Journals
(3)
Wiley Online Library
(2)
Oxford Journals
(1)
Oxford Journals 2020 Medicine
(1)
Ingenta
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(18)
British Journal Of Haematology
(2)
Cancer Discovery
(2)
American Society Of Clinical Oncology Educational Book
(1)
Europace
(1)
Journal Of Oncology Practice
(1)
The Angle Orthodontist
(1)
The Oncologist
(1)
The oncologist
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

FDA Approval Summary: Ramucirumab for Gastric Cancer

FDA Approval Summary: TAS-102

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Tissue-Agnostic Drug Development: A New Path to Drug Approval

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

FDA's Approach to Regulating Biosimilars

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

Biosimilars: Here and Now

When One Is a Hammer, Everything Looks Like a Nail

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome

Aktive Filter

Suchergebnisse filtern